Scarica l'app Stockscreener
3.37
4.33%
0.14
Precedente Chiudi:
$3.23
Aprire:
$3.4199
Volume 24 ore:
44,554
Relative Volume:
0.80
Capitalizzazione di mercato:
$338.99M
Reddito:
$73.01M
Utile/perdita netta:
$-67.89M
Rapporto P/E:
-4.9771
EPS:
-0.6771
Flusso di cassa netto:
$-43.68M
1 W Prestazione:
-2.88%
1M Prestazione:
-19.38%
6M Prestazione:
+1.51%
1 anno Prestazione:
+157.25%
Intervallo 1D:
$3.24
$3.42
Intervallo di 1 settimana:
$3.19
$3.49
Portata 52W:
$1.10
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
3.37 | 324.91M | 73.01M | -67.89M | -43.68M | -0.6771 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Ripresa | Jefferies | Buy |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2022-05-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-08 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Robert W. Baird | Outperform |
| 2020-03-06 | Downgrade | Goldman | Neutral → Sell |
| 2019-10-30 | Ripresa | Guggenheim | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-05-24 | Ripresa | Citigroup | Neutral |
| 2019-03-14 | Iniziato | William Blair | Outperform |
| 2018-12-19 | Iniziato | Goldman | Neutral |
| 2018-07-16 | Iniziato | Barclays | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2017-09-05 | Downgrade | SunTrust | Buy → Hold |
| 2017-09-05 | Reiterato | Wells Fargo | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-02-28 | Iniziato | Wells Fargo | Outperform |
| 2016-04-05 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-03-02 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | Iniziato | BofA/Merrill | Buy |
| 2015-04-20 | Iniziato | Jefferies | Buy |
| 2015-04-20 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Cellectis Adr Borsa (CLLS) Ultime notizie
Cellectis earnings beat by $0.10, revenue topped estimates - Investing.com
Cellectis (NASDAQ: CLLS) 2025 annual report shows losses and funding runway - Stock Titan
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - ChartMill
European ADRs Slipped As Biopharma Dragged The Pack - Finimize
European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Jefferies assumes coverage on Cellectis stock with Buy rating - Investing.com
European ADRs Started The Week Higher In US Trading - Finimize
ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView — Track All Markets
Traders are paying attention to the gapping stocks in Monday's session. - ChartMill
Clear Street initiates Cellectis stock with Buy rating on CAR-T potential - Investing.com
Working capital per share of Cellectis S.A. Sponsored ADR – NASDAQ:CLLS - TradingView — Track All Markets
European ADRs Inch Up As 3D Printer Materialise Leads Gains - Finimize
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Sahm
Arbitration ruling partially terminates Cellectis-Servier license agreement - Investing.com
European ADRs Stay Put As Novo Nordisk Slides - Finimize
12 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Moligo and Cellectis show promise in non-viral gene editing method - Investing.com India
Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications - Sahm
Cellectis reports breakthrough in non-viral gene editing technique - Investing.com
Citizens maintains Cellectis stock rating with $8 target ahead of ASH update - Investing.com
European ADRs Slip As Gains And Losses Balance Out - Finimize
Cellectis to Present a Development Update for eti-cel at ASH 2025 - Chartmill
European ADRs Dip As Biotech Stocks Tumble In US Trading - Finimize
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Barclays Remains a Buy on Cellectis SA (CLLS) - The Globe and Mail
Cellectis Adr Azioni (CLLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):